Lumida
/OCGN
⌘K
Ocugen Inc

Ocugen Inc

OCGN
$1.02USD-0.49%-0.00 today

MARKET CAP

345.9M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

OCGN remains in a Stage 2 advancing corrective reset with the active Bullish Pivot Point confirming structural repair. The recent volume-led breakout above resistance is positive, but price is extended above the rising 9/21 EMA zone and near overhead supply. Medium-term bias stays bullish in line with Stage 2, while short-term timing is unfavorable. We defer execution and stalk for a pullback into the supported EMA zone for cleaner entry. Primary risks include failure to hold the 9/21 EMA support and a reversal at the overhead resistance band.

  • Pivotal-stage gene therapy programs target retinitis pigmentosa and Stargardt disease for global approvals.
  • Planned BLA filings in 2027 with AMD therapy launch anticipated by 2028.
  • Q2 EPS loss of $0.07 and Q3 estimate of $0.06 reflect ongoing unprofitability.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$43,000$2.5M$6.0M$4.1M$4.4M
YoY %+142.6%-32.8%+8.8%
P / Sales4776.6x107.8x26.6x53.8x91.8x
EV / Sales4353.0x90.6x24.1x52.4x100.2x
Gross Profit, Adj.$43,000$2.5M$6.0M$4.1M$4.4M
YoY %+142.6%-32.8%+8.8%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit4353.0x90.6x24.1x52.4x100.2x
EBITDA, Adj.$-21.2M$-88.6M$-64.8M$-52.8M$-60.5M
YoY %-50.2%-53.3%+26.8%+18.6%-14.7%
Margin %-49262.8%-3560.7%-1074.0%-1301.8%-1371.6%
EV / EBITDA-8.8x-2.5x-2.2x-4.0x-7.3x
EBIT$-21.3M$-89.1M$-65.5M$-54.8M$-62.9M
YoY %-50.3%-53.5%+26.4%+16.4%-14.9%
Margin %-49500.0%-3580.0%-1085.7%-1350.4%-1425.7%
EV / EBIT-8.8x-2.5x-2.2x-3.9x-7.0x
Net Income$-34.4M$-86.8M$-63.1M$-54.1M$-67.8M
YoY %-69.8%-48.7%+27.3%+14.3%-25.5%
Net Margin-79925.6%-3488.9%-1045.0%-1333.0%-1537.4%
EPS (GAAP)-$0.31-$0.40-$0.26-$0.20-$0.23
YoY %+78.8%-33.3%+35.0%+23.1%-15.0%